Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexWith regards to recent information suggesting elevated cardiovascular risks for patients taking Celebrex, reaction from the medical community and the public has caused a dramatic drop in sales of this once leading blockbuster prescription pain reliever. On December 17, 2004, Pfizer, the manufacturer of Celebrex, announced that a recent clinical trial has indicated adverse cardiovascular Celebrex reaction risks for patients taking between 400 and 800 milligram doses of this analgesic medication. In the two weeks following this adverse Celebrex reaction information, new prescription sales of Celebrex have dropped more than fifty percent.
The National Cancer Institute had been conducting a clinical trial to test the effectiveness of Celebrex use in preventing colorectal and other cancers. This study was suspended after preliminary evidence suggested that patients taking 400 milligrams of Celebrex were at a 2.5 times greater risk of suffering adverse cardiovascular Celebrex reaction events. Trial participants who had been taking an 800 milligram dosage were 3.4 times more likely to experience a heart attack or cardiovascular stroke as a result of an adverse Celebrex reaction.
This new safety information regarding Celebrex prompted Pfizer to promise extensive investigation of all available research in order to properly assess the extent of potential cardiovascular Celebrex reaction events. The National Institutes of Health have ordered the review of forty agency-sponsored Celebrex clinical trials in an attempt to evaluate the Celebrex reaction risks. The Food and Drug Administration has urged the limiting of Celebrex use and has suggested that physicians and patients consider alternative treatment options until the exact nature of Celebrex reaction risks is better understood.
Pfizer has made no indication that the company plans to pull Celebrex off the market in response to Celebrex reaction risks. As urged by the FDA, Pfizer has temporarily pulled all direct marketing advertisements for Celebrex from television and other channels of mass communication. Prominent research centers are also modifying numerous cancer and arthritis clinical trials involving Celebrex until the exact nature of Celebrex reaction risks are understood.
Celebrex is a COX-2 selective non-steroidal anti-inflammatory drug that has become popular for its effectiveness in treating the pain associated with arthritis and a number of other health conditions. This drug was approved for use in the United States in 1999 and has had a relatively good safety record prior to recent adverse Celebrex reaction findings.
If you are currently taking Celebrex and are concerned about possible Celebrex reaction risks, you should contact your health care professional prior to making any changes in your treatment. Together, you and your doctor can decide if continuing Celebrex use or trying an alternative method of treatment is best for you. Civil lawsuits against Pfizer for their failure to adequately warn patients about possible Celebrex reaction risks are already being filed across the nation. To learn more about your legal rights and options in a case, you may wish to contact a qualified and experienced legal professional.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...